Skip to the main content.
Login Contact us

1 min read

Arterys Expanding AI-Powered Early Cancer Detection Technology Nationwide

Arterys Expanding AI-Powered Early Cancer Detection Technology Nationwide

Arterys and Whiterabbit.ai are collaborating in an AI-driven partnership to significantly increase breast cancer compliance. The program is designed to increase mammography screening compliance and volume and aid in early breast cancer detection. It also has the potential to reduce the backlog of missed preventive screenings that remain overdue due to the COVID-19 pandemic. 

Who is Whiterabbit.ai?

Whiterabbit.ai is an AI-technology company that targets late-stage diseases by providing more accurate and early cancer detection. Among their powerful solutions is their ACT AI-powered software purpose-built to dramatically increase breast cancer screening compliance. They achieve this by analyzing millions of data points and employing a personalized notification system that motivates women to comply with mammography recommendations. 

The ACT system has been tested in more than 300 U.S. breast cancer screening centers with more than a 20% growth year-over-year. Their solution helps save lives and eliminates the need for costly one-on-one follow ups.

Arterys' Partnership With Whiterabbit.ai

The program is designed to increase mammography screening compliance and volume and early detection of breast cancer. This union furthers Whiterabbit's mission to combat late-stage diseases through increased accessibility and integration of AI-powered healthcare software. 

Alexander Sardiña whiterabbit
As Whiterabbit's CEO Alexander Sardiña, MD notes:

“We believe AI has the power to transform healthcare through compliance and across the care continuum. Whiterabbit is dedicated to research and development of products in partnership with leading institutions and organizations that improve the accuracy and efficiency of detection and diagnosis and patient care, while reducing costs.” 

And we couldn't agree more. 

Arterys Dan Arnoff
Dan Arnoff, Arterys' Senior VP of Commercialization elaborates:

“ACT drives the compliance of screening mammograms which in turn reduces interval cancers. ACT combined with our current Breast AI solution for tomosynthesis provides the end user a very unique platform in the fight against breast cancer. Arterys is committed to developing the best of class AI solutions, deployed from a single cloud interface to maximize the power of AI to Breast Centers across the globe.” 

Through the partnership, clinics and hospitals already using Arterys' Breast AI platform to detect breast cancer, measure breast density, and deliver risk assessments can purchase and integrate ACT into their compliance programs. This successfully increases the number of women who schedule annual mammograms. 

To learn more about our exciting partnership with Whiterabbit.ai, please read the full press release.

Read the Full Press Release

NASCI 2022 Spotlights AI Benefits for Radiologists and Cardiologists

NASCI 2022 Spotlights AI Benefits for Radiologists and Cardiologists

NASCI 2022, an annual event organized by the North American Society of Cardiovascular Imaging (NASCI), finished off in Cleveland earlier this month....

Read More
Future of Radiology Platforms: Key Trends for Medical Imaging in 2022

Future of Radiology Platforms: Key Trends for Medical Imaging in 2022

Radiologists worldwide are looking to adopt medical imaging technologies that will transform the pace and standard of healthcare delivery. With the...

Read More
Arterys Expanding AI-Powered Early Cancer Detection Technology Nationwide

Arterys Expanding AI-Powered Early Cancer Detection Technology Nationwide

Arterys and Whiterabbit.ai are collaborating in an AI-driven partnership to significantly increase breast cancer compliance. The program is designed...

Read More